Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MYCN amplification
i
Other names:
MYCN, MYCN Proto-Oncogene BHLH Transcription Factor, V-Myc Avian Myelocytomatosis Viral Oncogene Neuroblastoma Derived Homolog, Class E Basic Helix-Loop-Helix Protein 37, N-Myc Proto-Oncogene Protein, BHLHe37, NMYC, Neuroblastoma-Derived V-Myc Avian Myelocytomatosis Viral Related Oncogene, Neuroblastoma MYC Oncogene, Oncogene NMYC, BHLHE37, MODED, N-Myc, ODED
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
4613
Related biomarkers:
Expression
Others
‹
›
Associations
(20)
News
Trials
Phase
Status
Apply
Phase
Status
Apply
A Study of N9 Chemotherapy in Children With Neuroblastoma (NCT04947501)
Phase 1
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Recruiting
Phase 1
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
06/11/2024
Initiation :
06/22/2021
Primary completion :
06/22/2025
Completion :
06/22/2025
MYCN
|
MYCN amplification
|
carboplatin • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • vincristine • topotecan • mesna • cyclophosphamide intravenous
Study of Oral MRT-2359 in Selected Cancer Patients (NCT05546268)
Phase 1/2
Monte Rosa Therapeutics, Inc
Monte Rosa Therapeutics, Inc
Recruiting
Phase 1/2
Monte Rosa Therapeutics, Inc
Recruiting
Last update posted :
06/11/2024
Initiation :
10/12/2022
Primary completion :
05/01/2026
Completion :
11/01/2027
MYC • MYCN
|
MYCN amplification • MYC expression
|
Xtandi (enzalutamide) • fulvestrant • MRT-2359
A Study of a Vaccine in Combination With β-glucan and GM-CSF in People With Neuroblastoma (NCT04936529)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Recruiting
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
06/07/2024
Initiation :
08/02/2021
Primary completion :
06/15/2025
Completion :
06/15/2025
MYC • MYCN • CSF2
|
MYCN amplification
PLX038 in Primary Central Nervous System Tumors Containing MYC or MYCN Amplifications (NCT06161519)
Phase 1/2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Recruiting
Phase 1/2
National Cancer Institute (NCI)
Recruiting
Last update posted :
06/05/2024
Initiation :
01/31/2024
Primary completion :
11/14/2028
Completion :
11/14/2033
MYCN
|
MYCN amplification
|
PLX038
Bivalent Vaccine With Escalating Doses of the Immunological Adjuvant OPT-821, in Combination With Oral β-glucan for High-Risk Neuroblastoma (NCT00911560)
Phase 1/2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 1/2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
06/05/2024
Initiation :
05/27/2009
Primary completion :
05/01/2025
Completion :
05/01/2025
MYCN
|
MYCN amplification
|
GD2-GD3 Vaccine
A Study of a Vaccine in Combination With Beta-glucan in People With Neuroblastoma (NCT06057948)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Recruiting
Phase 2
Memorial Sloan Kettering Cancer Center
Recruiting
Last update posted :
05/24/2024
Initiation :
09/21/2023
Primary completion :
03/21/2026
Completion :
03/21/2026
MYCN
|
MYCN amplification
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) (HR-NBL2) (NCT04221035)
Phase 3
Gustave Roussy, Cancer Campus, Grand Paris
Gustave Roussy, Cancer Campus, Grand Paris
Recruiting
Phase 3
Gustave Roussy, Cancer Campus, Grand Paris
Recruiting
Last update posted :
05/15/2024
Initiation :
11/05/2019
Primary completion :
11/01/2026
Completion :
11/01/2032
MYCN • MYCL
|
MYCN amplification • MYCL amplification
|
cisplatin • carboplatin • temozolomide • doxorubicin hydrochloride • cyclophosphamide • ifosfamide • etoposide IV • irinotecan • vincristine • dacarbazine • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • cyclophosphamide intravenous • vindesine
Local Control With Reduced-dose Radiotherapy for High-Risk Neuroblastoma (NCT02245997)
Phase N/A
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase N/A
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
04/25/2024
Initiation :
09/01/2014
Primary completion :
09/01/2024
Completion :
09/01/2024
MYCN
|
MYCN amplification
Safety Study of Dinutuximab Combined With Immunotherapy to Treat Neuroblastoma (NCT02169609)
Phase 2
Fundació Sant Joan de Déu
Fundació Sant Joan de Déu
Completed
Phase 2
Fundació Sant Joan de Déu
Completed
Last update posted :
04/22/2024
Initiation :
11/26/2014
Primary completion :
12/26/2016
Completion :
12/31/2018
MYCN
|
MYCN amplification
|
Unituxin (dinutuximab) • Leukine (sargramostim)
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (NCT03126916)
Phase 3
Children's Oncology Group
Children's Oncology Group
Active, not recruiting
Phase 3
Children's Oncology Group
Active, not recruiting
Last update posted :
04/22/2024
Initiation :
05/14/2018
Primary completion :
09/30/2026
Completion :
09/30/2026
MYCN
|
MYCN amplification
|
cisplatin • Xalkori (crizotinib) • carboplatin • Lorbrena (lorlatinib) • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • busulfan • Unituxin (dinutuximab) • Azedra (iobenguane I 131) • Leukine (sargramostim) • captisol-enabled melphalan • cyclophosphamide intravenous • dexrazoxane
Dinutuximab, Sargramostim, and Combination Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (NCI-2018-03732) (NCT03786783)
Phase 2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Active, not recruiting
Phase 2
National Cancer Institute (NCI)
Active, not recruiting
Last update posted :
04/17/2024
Initiation :
03/04/2019
Primary completion :
12/31/2021
Completion :
09/22/2024
MYCN • IL6 • CXCL9
|
MYCN amplification • IL6 expression
|
cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • daunorubicin • topotecan • melphalan • thiotepa • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim) • cyclophosphamide intravenous • dexrazoxane
Biomarkers in Tumor Tissue Samples From Patients With Newly Diagnosed Neuroblastoma or Ganglioneuroblastoma (NCT00904241)
Phase N/A
Children's Oncology Group
Children's Oncology Group
Recruiting
Phase N/A
Children's Oncology Group
Recruiting
Last update posted :
04/16/2024
Initiation :
11/06/2000
Primary completion :
01/01/2100
MYCN
|
MYCN amplification
Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (PEDS-PLAN) (NCT02559778)
Phase 2
Giselle Sholler
Giselle Sholler
Recruiting
Phase 2
Giselle Sholler
Recruiting
Last update posted :
04/08/2024
Initiation :
09/01/2015
Primary completion :
09/01/2030
Completion :
09/01/2035
MYCN
|
MYCN amplification
|
dasatinib • sorafenib • Zykadia (ceritinib) • Zolinza (vorinostat)
Naxitamab Added to Induction for Newly Diagnosed High-Risk Neuroblastoma (NCT05489887)
Phase 2
Giselle Sholler
Giselle Sholler
Recruiting
Phase 2
Giselle Sholler
Recruiting
Last update posted :
04/08/2024
Initiation :
09/14/2022
Primary completion :
09/01/2026
Completion :
09/01/2033
MYCN
|
MYCN amplification
|
Zykadia (ceritinib) • Danyelza (naxitamab-gqgk)
DFMO as Maintenance Therapy for Molecular High/Very High Risk and Relapsed Medulloblastoma (NCT04696029)
Phase 2
Giselle Sholler
Giselle Sholler
Recruiting
Phase 2
Giselle Sholler
Recruiting
Last update posted :
04/08/2024
Initiation :
03/29/2021
Primary completion :
03/01/2028
Completion :
03/01/2029
TP53 • MYC • MYCN
|
TP53 mutation • MYCN amplification • TP53 amplification
Molecular-Guided Therapy for Childhood Cancer (NCT02162732)
Phase N/A
Giselle Sholler
Giselle Sholler
Completed
Phase N/A
Giselle Sholler
Completed
Last update posted :
04/05/2024
Initiation :
07/08/2014
Primary completion :
01/18/2024
Completion :
01/18/2024
MYCN
|
MYCN amplification
Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer (NCT03936465)
Phase 1
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Active, not recruiting
Phase 1
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
03/21/2024
Initiation :
09/27/2019
Primary completion :
07/16/2024
Completion :
07/16/2024
MYC • MYCN • BRD4 • BRD3
|
MYCN amplification
|
ezobresib (BMS-986158) • trotabresib (BMS-986378)
Busulfan, Melphalan, and Stem Cell Transplant After Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma (NCT01798004)
Phase 1
Children's Oncology Group
Children's Oncology Group
Active, not recruiting
Phase 1
Children's Oncology Group
Active, not recruiting
Last update posted :
03/13/2024
Initiation :
04/08/2013
Primary completion :
07/28/2015
MYCN
|
MYCN amplification • MYCN expression
|
cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • busulfan • Neupogen (filgrastim) • cyclophosphamide intravenous
Trial of CUDC-907 in Children and Young Adults With Relapsed or Refractory Solid Tumors, CNS Tumors, or Lymphoma (NCT02909777)
Phase 1
Dana-Farber Cancer Institute
Dana-Farber Cancer Institute
Active, not recruiting
Phase 1
Dana-Farber Cancer Institute
Active, not recruiting
Last update posted :
03/11/2024
Initiation :
10/01/2016
Primary completion :
07/01/2024
Completion :
07/01/2024
MYC • MYCN
|
MYCN amplification • MYC expression • MYCN expression
|
fimepinostat (CUDC-907)
Auto Transplant for High Risk or Relapsed Solid or CNS Tumors (NCT01505569)
Phase N/A
Masonic Cancer Center, University of Minnesota
Masonic Cancer Center, University of Mi...
Completed
Phase N/A
Masonic Cancer Center, University of Minnesota
Completed
Last update posted :
02/26/2024
Initiation :
10/20/2011
Primary completion :
02/01/2024
Completion :
02/01/2024
MYCN • CD34
|
LDH elevation • MYCN amplification • MYCN expression
|
cisplatin • carboplatin • paclitaxel • ifosfamide • etoposide IV • melphalan • mesna • thiotepa • busulfan
Biological Characterisation of High Risk CHildhood Cancer in Children, Adolescents and Young Adults (MICCHADO) (NCT03496402)
Phase N/A
Institut Curie
Institut Curie
Recruiting
Phase N/A
Institut Curie
Recruiting
Last update posted :
02/05/2024
Initiation :
04/20/2018
Primary completion :
04/19/2027
Completion :
08/19/2027
MYCN
|
MYCN amplification
Humanized Anti-GD2 Antibody Hu3F8 and Allogeneic Natural Killer Cells for High-Risk Neuroblastoma (NCT02650648)
Phase 1
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 1
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
02/02/2024
Initiation :
01/01/2016
Primary completion :
01/01/2025
Completion :
01/01/2025
MYCN
|
MYCN amplification
|
cyclophosphamide • Danyelza (naxitamab-gqgk) • cyclophosphamide intravenous
Therapy for Children With Advanced Stage Neuroblastoma (NCT01857934)
Phase 2
St. Jude Children's Research Hospital
St. Jude Children's Research Hospital
Active, not recruiting
Phase 2
St. Jude Children's Research Hospital
Active, not recruiting
Last update posted :
01/15/2024
Initiation :
07/05/2013
Primary completion :
10/21/2021
Completion :
12/01/2024
MYCN
|
MYCN amplification
|
cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • mesna • Proleukin (aldesleukin) • busulfan • Unituxin (dinutuximab) • Leukine (sargramostim) • Neupogen (filgrastim) • cyclophosphamide intravenous • humanised dinutuximab (Hu14.18K322A)
Combination Therapy of Antibody Hu3F8 With Granulocyte- Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Relapsed/Refractory High-Risk Neuroblastoma (NCT01757626)
Phase 1/2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 1/2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
01/05/2024
Initiation :
12/01/2012
Primary completion :
12/01/2025
Completion :
12/01/2025
MYC • MYCN
|
MYCN amplification
|
cyclophosphamide • irinotecan • Danyelza (naxitamab-gqgk)
Induction Therapy Including 131 I-MIBG and Chemotherapy in Treating Patients With Newly Diagnosed High-Risk Neuroblastoma Undergoing Stem Cell Transplant, Radiation Therapy, and Maintenance Therapy With Isotretinoin (NCT01175356)
Phase 1
Children's Oncology Group
Children's Oncology Group
Active, not recruiting
Phase 1
Children's Oncology Group
Active, not recruiting
Last update posted :
01/04/2024
Initiation :
10/04/2010
Primary completion :
09/28/2016
Completion :
09/28/2024
MYCN
|
MYCN amplification
|
cisplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • vincristine • topotecan • melphalan • busulfan • Azedra (iobenguane I 131) • cyclophosphamide intravenous
MCT for the Harvard/UCSF ROBIN Center (NCT06000787)
Phase N/A
Brigham and Women's Hospital
Brigham and Women's Hospital
Recruiting
Phase N/A
Brigham and Women's Hospital
Recruiting
Last update posted :
12/12/2023
Initiation :
09/19/2023
Primary completion :
08/31/2028
Completion :
08/31/2028
MYCN
|
MYCN amplification
|
Azedra (iobenguane I 131)
Personalized Risk-Adapted Therapy in Post-Pubertal Patients With Newly-Diagnosed Medulloblastoma (PersoMed-I) (NCT04402073)
Phase 2
European Organisation for Research and Treatment of Cancer - EORTC
European Organisation for Research and ...
Recruiting
Phase 2
European Organisation for Research and Treatmen...
Recruiting
Last update posted :
12/11/2023
Initiation :
11/11/2022
Primary completion :
03/01/2030
Completion :
03/01/2030
TP53 • BRCA2 • MYCN
|
TP53 wild-type • MYCN amplification
|
cisplatin • vincristine • lomustine • Odomzo (sonidegib)
PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study (NCT02307630)
Phase N/A
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase N/A
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
12/04/2023
Initiation :
11/01/2014
Primary completion :
11/01/2024
Completion :
11/01/2024
MYCN
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) (ANBL19P1) (NCT04385277)
Phase 2
Children's Oncology Group
Children's Oncology Group
Active, not recruiting
Phase 2
Children's Oncology Group
Active, not recruiting
Last update posted :
11/21/2023
Initiation :
12/31/2020
Primary completion :
06/30/2023
Completion :
09/26/2024
MYCN
|
MYCN amplification
|
temozolomide • irinotecan • Qarziba (dinutuximab beta) • Unituxin (dinutuximab) • Leukine (sargramostim)
An Intermediate Expanded Use Trial of DFMO (NCT03581240)
Phase N/A
Giselle Sholler
Giselle Sholler
Available
Phase N/A
Giselle Sholler
Available
Last update posted :
09/28/2023
MYCN
|
MYCN amplification • MYCN expression
Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid Tumors (NCT02095132)
Phase 1/2
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Completed
Phase 1/2
National Cancer Institute (NCI)
Completed
Last update posted :
09/26/2023
Initiation :
03/28/2014
Primary completion :
12/31/2020
Completion :
06/30/2023
MYCN • AFP
|
MYCN amplification
|
adavosertib (AZD1775) • irinotecan
Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. (NCT06047535)
Phase 4
SciClone Pharmaceuticals
SciClone Pharmaceuticals
Not yet recruiting
Phase 4
SciClone Pharmaceuticals
Not yet recruiting
Last update posted :
09/21/2023
Initiation :
10/31/2023
Primary completion :
06/15/2027
Completion :
08/15/2027
MYCN
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
Study of Chemoimmunotherapy for High-Risk Neuroblastoma (NCT03189706)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
09/12/2023
Initiation :
06/12/2017
Primary completion :
06/01/2024
Completion :
06/01/2024
MYCN
|
MYCN amplification
|
temozolomide • irinotecan • Danyelza (naxitamab-gqgk) • Leukine (sargramostim)
European Low and Intermediate Risk Neuroblastoma Protocol (NCT01728155)
Phase 3
Instituto de Investigacion Sanitaria La Fe
Instituto de Investigacion Sanitaria La Fe
Completed
Phase 3
Instituto de Investigacion Sanitaria La Fe
Completed
Last update posted :
09/08/2023
Initiation :
01/01/2011
Primary completion :
12/31/2022
MYCN
|
MYCN amplification
Humanized 3F8 Monoclonal Antibody (Hu3F8) in Patients With High-Risk Neuroblastoma and GD2-Positive Tumors (NCT01419834)
Phase 1
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Completed
Phase 1
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
08/04/2023
Initiation :
08/15/2011
Primary completion :
08/02/2023
Completion :
08/02/2023
MYCN
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
A Study of the Effect of Hu3F8/GM-CSF Immunotherapy Plus Isotretinoin in Patients in First Remission of High-Risk Neuroblastoma (NCT03033303)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Phase 2
Memorial Sloan Kettering Cancer Center
Active, not recruiting
Last update posted :
07/04/2023
Initiation :
01/23/2017
Primary completion :
06/01/2024
Completion :
06/01/2024
MYCN
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
Naxitamab and GM-CSF in People With Neuroblastoma (NCT04501757)
Phase N/A
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
No Longer Available
Phase N/A
Memorial Sloan Kettering Cancer Center
No Longer Available
Last update posted :
12/08/2022
MYCN
|
MYCN amplification
|
Danyelza (naxitamab-gqgk)
Monoclonal Antibody 3F8 and Sargramostim in Treating Patients With Neuroblastoma (NCT00072358)
Phase 2
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Completed
Phase 2
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
05/16/2022
Initiation :
07/01/2003
Primary completion :
01/15/2021
Completion :
01/15/2021
MYCN • CSF2
|
MYCN amplification
|
temozolomide • irinotecan • Leukine (sargramostim)
Comparing Two Different Myeloablation Therapies in Treating Young Patients Who Are Undergoing a Stem Cell Transplant for High-Risk Neuroblastoma (NCT00567567)
Phase 3
Children's Oncology Group
Children's Oncology Group
Completed
Phase 3
Children's Oncology Group
Completed
Last update posted :
04/28/2022
Initiation :
11/05/2007
Primary completion :
02/27/2015
Completion :
03/31/2022
CD8 • MYCN • UGT1A1 • CD4
|
MYCN amplification • UGT1A1*1*1
|
cisplatin • carboplatin • doxorubicin hydrochloride • cyclophosphamide • etoposide IV • topotecan • melphalan • Marqibo (vincristine liposomal) • thiotepa • Neupogen (filgrastim) • cyclophosphamide intravenous
Beta-Glucan and Monoclonal Antibody 3F8 in Treating Patients With Metastatic Neuroblastoma (NCT00492167)
Phase 1
Memorial Sloan Kettering Cancer Center
Memorial Sloan Kettering Cancer Center
Completed
Phase 1
Memorial Sloan Kettering Cancer Center
Completed
Last update posted :
03/07/2022
Initiation :
09/09/2005
Primary completion :
03/04/2022
Completion :
03/04/2022
MYCN
|
MYCN amplification
Share
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login